Characterizing the Pharmacokinetic Profile of a Novel Encapsulated Caffeine Beverage and Associated Mood and Physiological Effects

Sponsor

PepsiCo Global R&D (Industry)

Overall Status

Completed

CT.gov ID

NCT05096780

Collaborator

(none)

Enrollment

Location

Arms

Actual Duration (Months)

18.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study is designed to compare self-reported mood states for encapsulated caffeine compared to dose-matched free caffeine, when consumed as a ready-to-drink beverage in healthy subjects. Additionally, this study will characterize the plasma caffeine pharmacokinetic profile for the encapsulated and free caffeine beverages. Two different caffeine levels, 160 and 250 mg will be included, which represent more common caffeine consumption from typical energy drinks.

The primary outcomes are alertness ratings from the Caffeine Research visual analog scale (VAS) and PK parameters over 12 hours. Secondary outcomes are Caffeine Research VAS scores (beyond alertness), three other symptom VAS scores, and vital signs for safety.

Condition or Disease	Intervention/Treatment	Phase
Alertness	Other: Flavored caffeinated beverage	Phase 1

Study Design

Study Type:

Interventional

Actual Enrollment :

75 participants

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Masking Description:

Double-blinded

Primary Purpose:

Basic Science

Official Title:

Characterizing the Pharmacokinetic Profile of a Novel Encapsulated Caffeine Beverage and Associated Mood and Physiological Effects

Actual Study Start Date :

Oct 8, 2021

Actual Primary Completion Date :

Feb 6, 2022

Actual Study Completion Date :

Feb 6, 2022

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Beverage 1 Free caffeine 160 mg	Other: Flavored caffeinated beverage 16.9 oz (500 cc), carbonated, zero calorie
Experimental: Beverage 2 Encapsulated caffeine 160 mg	Other: Flavored caffeinated beverage 16.9 oz (500 cc), carbonated, zero calorie
Active Comparator: Beverage 3 Free caffeine 250 mg	Other: Flavored caffeinated beverage 16.9 oz (500 cc), carbonated, zero calorie
Experimental: Beverage 4 Encapsulated caffeine 250 mg	Other: Flavored caffeinated beverage 16.9 oz (500 cc), carbonated, zero calorie

Outcome Measures

Primary Outcome Measures

Alertness [Changes from pre-dose baseline to 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post beverage ingestion]
A self-reported mood measurement from the Caffeine Research Visual Analog Scale (VAS) rated from 0 (not at all) to 100 mm (extremely alert), to compare dose-matched free caffeine to encapsulated caffeine. Longer-lasting alertness would be a benefit.
Plasma caffeine PK profile of (AUC0-t, AUC0-inf) [Changes from pre-dose baseline to 12 hours after the first sip of beverage.]
Plasma sampling at 19 time points: Pre-dose baseline, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 9, 10, 11 and 12 hours post first sip of beverage ingestion to characterize dose-matched free caffeine compared to encapsulated caffeine for plasma caffeine (AUC0-t, AUC0-inf)
Plasma caffeine PK profile of peak caffeine concentration (Cmax) [Changes from pre-dose baseline to 12 hours after the first sip of beverage.]
Plasma sampling at 19 time points: Pre-dose baseline, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 9, 10, 11 and 12 hours post first sip of beverage ingestion to characterize dose-matched free caffeine compared to encapsulated caffeine for plasma caffeine peak caffeine concentration (Cmax)
Plasma caffeine PK profile of time to maximal plasma caffeine concentration (Tmax) [Changes from pre-dose baseline to 12 hours after the first sip of beverage.]
Plasma sampling at 19 time points: Pre-dose baseline, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 9, 10, 11 and 12 hours post first sip of beverage ingestion to characterize dose-matched free caffeine compared to encapsulated caffeine for plasma caffeine time to maximal plasma caffeine concentration (Tmax)
Plasma caffeine PK profile of half-life (t1/2) [Changes from pre-dose baseline to 12 hours after the first sip of beverage.]
Plasma sampling at 19 time points: Pre-dose baseline, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 9, 10, 11 and 12 hours post first sip of beverage ingestion to characterize dose-matched free caffeine compared to encapsulated caffeine for plasma caffeine half-life (t1/2)
Plasma caffeine PK profile of plasma caffeine concentration by time [Changes from pre-dose baseline to 12 hours after the first sip of beverage.]
Plasma sampling at 19 time points: Pre-dose baseline, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 9, 10, 11 and 12 hours post first sip of beverage ingestion to characterize dose-matched free caffeine compared to encapsulated caffeine for plasma caffeine concentration by time

Secondary Outcome Measures

The 6 other Caffeine Research Visual Analog Scale (VAS) symptom ratings besides alertness [Changes from pre-dose baseline to 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post beverage ingestion]
Self-reported Caffeine Research Visual Analog Scale (VAS) ratings from 0-100 mm representing the full range of each dimension (relaxed, jittery, tired, tense, headache, overall mood) to compare dose-matched free caffeine to encapsulated caffeine. More relaxed, less jittery, less tired, less tense, no headache and better mood would be better.
3 additional other symptoms Visual Analog Scale (VAS) ratings [Changes from pre-dose baseline to 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post beverage ingestion]
Self-reported caffeine symptoms (lightheaded, irritable, pounding heartbeat) rated on a Visual Analog Scale (VAS) from 0 (not at all) to 100 mm (extremely) to compare dose-matched free caffeine to encapsulated caffeine. Absence of these would be better.
Blood pressure [Changes from pre-dose baseline to 2 and 6 hours post beverage ingestion]
Vital sign for safety monitoring. Resting blood pressures within normal limits would be better.
Heart rate [Changes from pre-dose baseline to 2 and 6 hours post beverage ingestion]
Vital sign for safety monitoring. Resting heart rates within normal limits would be better.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 55 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Healthy adult male and female volunteers aged 18 to 55 years
Have a BMI of 18 to 32.49 kg/m2 (inclusive)
Are regular caffeine consumers (average 1 to 3 caffeine-containing beverages per day, not to exceed 400 mg/ per day)
Willing to commit to 4 long test days (~15-16 hrs)
Able to comprehend and willing to sign an Informed Consent Form (ICF)
Willing to avoid caffeine-containing products for ≥48 hrs prior to visits and until the completion of each test visit
Willing to avoid alcohol for ≥24 hrs prior to visits
Willing to fast 10 hrs prior to visits
Willing to stick to their usual dietary patterns and avoid grapefruit
Willing to stick to their usual physical activity level throughout the study
Willing to stick to their usual sleep pattern
No participation in any clinical trial within the past 30 days and throughout this study, or any PEP protocol within the past 6 months

Exclusion Criteria:

Subjects will be excluded from the study if they have:

Reported history or clinical manifestations of significant metabolic (including type1 or type 2 diabetes mellitus), hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, urological, neurological, or psychiatric disorders unless deemed clinically not significant by investigator
Current or recent history (<30 days prior to Screening) of a clinically significant bacterial, fungal, or mycobacterial infection
Current clinically significant viral infection
History of malignancy, with the exception of cured basal cell or squamous cell carcinoma of the skin
Are pregnant or breastfeeding or planning to become pregnant
Resting heart rate less than 45 bpm or greater than 100 bpm
History of unstable ischemic heart disease or uncontrolled hypertension (blood pressure greater than or equal to 50/90 mm Hg)
History of significant surgery that may affect absorption of caffeine. Appendectomy and/or cholecystectomy will be allowed
Presence of a malabsorption syndrome possibly affecting drug/Product absorption (e.g., Crohn's disease or chronic pancreatitis)
Extreme dietary habits, including but not limited to intentional consumption of a high fiber diet, gluten-free, low-carb, vegan, ketogenic
History of alcoholism or drug addiction within 1 year prior to Screening, or current alcohol or drug use that, in the opinion of the investigator, will interfere with the subject's ability to comply with the dosing schedule and study evaluations
One or more tobacco-containing or nicotine-containing product occasions per month on average, or use of such products within 48 hours prior to dosing of each study period
Use of any prescription or nonprescription drugs (including vitamins, minerals, and phytotherapeutic, herbal, or plant-derived preparations) is prohibited within 7 days prior to the dose of study product, unless deemed acceptable by the Investigator
Use of any medication known to have an interaction with caffeine including oral contraceptives (e.g., medications metabolized via the CYP1A2 pathway)
Donation of blood in excess of 500 ml within 4 weeks prior to study entry or of plasma within 2 weeks prior to Screening
Receipt of blood products within 3 months prior to study entry
Subjects who, in the opinion of the investigator, are unable or unlikely to comply with the dosing schedule and study evaluations